Sign up to save your podcasts
Or
Share Ep. 156 - JPM Highlights & Alzheimer's Takeaways
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ep. 156 - JPM Highlights & Alzheimer's Takeaways
A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.
Reach us by sending a text
View all episodes
By BioCentury
4.8
3131 ratings
A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.
Reach us by sending a text
More shows like BioCentury This Week
View all
Exchanges
962 Listeners
WSJ What’s News
4,338 Listeners
Bloomberg Intelligence
400 Listeners
Odd Lots
1,932 Listeners
Bloomberg Businessweek
423 Listeners
The Readout Loud
322 Listeners
The Journal.
6,089 Listeners
Biotech 2050 Podcast
62 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,926 Listeners
Business Of Biotech
86 Listeners
Biotech Hangout
18 Listeners
The Markets
79 Listeners
Ground Truths
51 Listeners
The Top Line
13 Listeners
The BioCentury Show
12 Listeners